Safety and Efficacy of Intravenous Tirofiban in Acute Ischemic Stroke Patient without Large Arterial Occlusion

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIN-17013510

Enrollment

Unknown

Registered

2017-11-23

Start date

2017-12-01

Completion date

Unknown

Last updated

2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Interventions

tirofiban group:intravenous tirofiban

Control group:Simple expansion, antiplatelet or anticoagulant therapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) acute ischemic stroke patient aged =18 years old, no visible arterial occlusion on the CTA or MRA; 2) NIHSS score =4 on admission; 3) patient or his/her relative is willing to participate in the study and to provide informed consent; 4) ischemic stroke patients presented between 4; 5 hours to 24 hours from symptom onset.

Exclusion criteria

Exclusion criteria: 1) Hemorrhagic transformation; 2) Pre-stroke mRS = 2; 3) History of severe bleeding or major surgery within 30 days; 4) Coexistent terminal illness with life expectancy = 12 months; 5) Any known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency, or taking oral anticoagulant with INR > 1.7; 6) Platelet count < 100,000/mm3; 7) Hemoglobin < 10 g/dL; 8) A serum glucose level= 50 mg/dl; or 9) Severe renal insufficiency with creatinine clearance rate <30ml/min.

Design outcomes

Primary

Measure	Time frame
intracerebral hemorrhage transformation;severe bleeding;NIHSS score;mRS score;mortality;	—

Countries

China

Contacts

Public ContactZhang Meng

Neurology Department, Daping Hospital, Third Military Medical University

zhangmeng861@gmail.com+86 023 68757816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026